JANX Janux Therapeutics Inc
Price (delayed)
$49.35
Market cap
$2.57B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.9
Enterprise value
$2.58B
Highlights
JANX's equity has surged by 120% year-on-year
JANX's gross profit has soared by 108% QoQ and by 95% YoY
The quick ratio is down by 8% since the previous quarter
Key stats
What are the main financial stats of JANX
Market
Valuations
Earnings
Shares outstanding
52.16M
Market cap
$2.57B
Enterprise value
$2.58B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.89
Price to sales (P/S)
177.64
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
170.73
Revenue
$15.13M
EBIT
-$44.05M
EBITDA
-$41.98M
Free cash flow
-$47.75M
Per share
Balance sheet
Liquidity
EPS
-$0.9
Free cash flow per share
-$0.88
Book value per share
$12.68
Revenue per share
$0.28
TBVPS
$12.7
Total assets
$691.41M
Total liabilities
$33.74M
Debt
$23.82M
Equity
$657.68M
Working capital
$650.39M
Debt to equity
0.04
Current ratio
57.34
Quick ratio
56.7
Net debt/EBITDA
-0.2
Margins
Efficiency
Dividend
EBITDA margin
-277.5%
Gross margin
100%
Net margin
-291.2%
Operating margin
-435.9%
Return on assets
-8.2%
Return on equity
-8.8%
Return on invested capital
-9.1%
Return on capital employed
-6.5%
Return on sales
-291.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
JANX stock price
How has the Janux Therapeutics stock price performed over time
Intraday
-0.22%
1 week
12.9%
1 month
19.43%
1 year
390.07%
YTD
359.93%
QTD
17.81%
Financial performance
How have Janux Therapeutics's revenue and profit performed over time
Revenue
$15.13M
Gross profit
$15.13M
Operating income
-$65.93M
Net income
-$44.05M
Gross margin
100%
Net margin
-291.2%
JANX's gross profit has soared by 108% QoQ and by 95% YoY
The revenue has soared by 108% from the previous quarter and by 95% YoY
Janux Therapeutics's net margin has surged by 67% YoY and by 62% QoQ
The operating margin has soared by 56% from the previous quarter and by 56% YoY
Growth
What is Janux Therapeutics's growth rate over time
Valuation
What is Janux Therapeutics stock price valuation
P/E
N/A
P/B
3.89
P/S
177.64
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
170.73
The EPS has grown by 45% YoY and by 26% from the previous quarter
JANX's equity has surged by 120% year-on-year
JANX's P/B is 70% above its last 4 quarters average of 2.3
The revenue has soared by 108% from the previous quarter and by 95% YoY
The P/S is 38% more than the last 4 quarters average of 129.3
Efficiency
How efficient is Janux Therapeutics business performance
The ROS has soared by 67% YoY and by 62% from the previous quarter
JANX's return on equity has surged by 59% year-on-year and by 35% since the previous quarter
The ROA has soared by 57% YoY and by 34% from the previous quarter
The return on invested capital has surged by 57% year-on-year and by 36% since the previous quarter
Dividends
What is JANX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for JANX.
Financial health
How did Janux Therapeutics financials performed over time
Janux Therapeutics's total assets has surged by 102% YoY
The total liabilities has contracted by 20% YoY
Janux Therapeutics's debt is 96% lower than its equity
JANX's equity has surged by 120% year-on-year
Janux Therapeutics's debt to equity has plunged by 50% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.